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Peptidomimetic imidazolidin-4-one derivatives of primaquine (imidazoquines) recently displayed in
vitro activity against blood schizonts of a chloroquine-resistant strain of Plasmodium falciparum.
Preliminary studies with a subset of such imidazoquines showed them to both block transmission of
P. berghei malaria from mouse to mosquito and be highly stable toward hydrolysis at physiological
conditions. This prompted us to have deeper insight into the activity of imidazoquines against both
Plasmodia and Pneumocystis carinii, on which primaquine is also active. Full assessment of the in vivo
transmission-blocking activity of imidazoquines, in vitro tissue-schizontocidal activity on P. berghei-
infected hepatocytes, and in vitro anti-P. carinii activity is now reported. All compounds were active in
these biological assays, with generally lower activity than the parent drug. However, imidazoquines’
stability against both oxidative deamination and proteolytic degradation suggest that theywill probably
have higher oral bioavailability and lower hematotoxicity than primaquine, which might translate into
higher therapeutic indexes.
Introduction
8-Aminoquinolines (8-AQa) are an important class of anti-
microbial agents, with important roles in the treatment of
malaria and Pneumocystis infection.1 Considering malaria,
primaquine (1, Scheme 1) is still the only clinically available 8-
AQ active against both gametocytes, responsible for disease
transmission between the human host and the mosquito
vector, and all exoerythrocytic forms (EEFs) of Plasmodia,
including the liver hypnozoites responsible for relapses of
vivax and ovale malarias.2-5 Primaquine (PQ) is also useful
for the treatment of Pneumocystis infections5 caused by
Pneumocystis jirovecii (formerly P. carinii f. sp. hominis6,7),
which is a common cause of pneumonia in immunocompro-
mised individuals and frequently the first serious illness
encountered by HIV-infected patients.8-11 P. jirovecii also
infects other immunocompromised individuals such as those
undergoing cancer therapy and organ and bone marrow
transplants.12 Unfortunately, PQ has low oral bioavailability
because it is rapidly metabolized to the inactive metabo-
lite carboxyprimaquine (2, Scheme 1) by oxidative deamina-
tion13,14 and presents blood toxicity, namely hemolytic ane-
mia after primary induction of methemoglobinemia.4,15-17
Hematotoxicity is greatest in those with deficiency in glucose-
6-phosphate dehydrogenase (6GPD) and is further aggra-
vated by the need of frequent administration of high PQdoses
in order to compensate for its low oral bioavailability.1-5 We
previously reported that N-acylation of PQ with amino acids
or dipeptides (3, Scheme 1) leads to active structures not
susceptible to oxidative deamination to 2 but sensitive to
degradation by amino- and endopeptidases.18 We now set
out to explore the effect of introducing an imidazolidin-4-one
Scheme 1. Chemical Structures for Primaquine and Relevant
Derivatives (See Text)
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moiety in such N-acyl-PQ derivatives on the stability and
bioactivity of the resulting compounds. Imidazolidin-4-one
structures are often used to protect theN-terminal residues of
peptides and peptidomimetics19-23 as well as to mimetize the
amino acid proline.24 In this context, we prepared imidazoli-
din-4-ones 4 (Scheme 1)25 and found them to be promising
therapeutic agents given their significant activity in blocking
the transmission of P. berghei malaria from mice to mosqui-
toes,26 remarkable stability in pH 7.4 buffer and human
plasma,26,27 and overall activity profile comparable to that
of the parent drug against Plasmodia and Pneumocystis
carinii.28
In view of initial promising results, we undertook the N1-
acylation of imidazolidin-4-ones 4 with amino acids, i.e., the
preparation of structures 5 (Scheme 1)29 aimed at (i) fully
suppressing hydrolysis of the imidazolidin-4-one ring through
acylation of its N-1 nitrogen, (ii) increasing the compounds’
aqueous solubility by insertion of a basic amino group, and
(iii) potentially increasing the compounds’ antimalarial activ-
ity, given the relevant role usually attributed to the basic
amino group of PQ.18A set of different structures 5, where the
amino acids’ side chains (R1 and R2) were varied, was
prepared in order to check for the influence of these substit-
uents on compoundproperties. Preliminary biological evalua-
tion of compounds 5 demonstrated blood-schizontocidal
activity against a chloroquine-resistant strain ofP. falciparum
as well as the ability to block transmission of P. berghei
malaria between Balb/C mice and Anopheles stephensi mos-
quitoes.30 These results prompted us to further evaluate
compounds 5 as antimalarial tissue-schizontocides and
against P. carinii.
Results and Discussion
Chemistry. Compounds 4 were obtained and further N1-
acylated by previously reported methods through the syn-
thetic route depicted in Scheme 2.29,30 Briefly, once prepared
as previously described,29 imidazolidin-4-one precursors 4
were coupled toNR-Boc-protected amino acids (BocAAOH)
by means of a carbodiimide (diisopropylcarbodiimide, DIC)
as condensation agent, in the presence of 1-hydroxybenzo-
triazole (HOBt) as auxiliary nucleophile. Boc was then
removed from the condensation product by acidolysis with
trifluoroacetic acid (TFA), yielding the target compounds 5
in good yields andwith correct spectroscopic data. It is worth
mentioning that bulky R1 side chains impair N-acylation of
imidazolidin-4-ones 4, which limited the synthesis of struc-
tures 5 to those where R1 was either H or Me (respectively,
glycine and alanine derivatives). Nonetheless, our previous
work has shown that R1 substituents on imidazolidin-4-ones
4 (i) should be small (H, Me) for higher transmission block-
ing activities2 and (ii) do not have a marked influence on
compounds activity against both blood-stage P. falciparum
or P. carinii.28 Bulky substituents on the imidazolidin-4-
one’s C-2 carbon are also detrimental towardN-acylation, so
only propanone-derived imidazolidin-4-ones are efficiently
N-acylated.29 Nevertheless, insertion of larger substituents
on the imidazolidin-4-one’s C-2, as those previously reported
by us,26,28 would probably lead to a decreased water-solubi-
lity of final compounds 5. So, structural diversity of the latter
was achieved by varying the second amino acid side chain
(R2, see Table 1) in order to check for the influence of this
substituent on compound’s bioactivity.
The N-acetyl and N,N0-diacetyl imidazolidin-4-one deri-
vatives 6 and 7, also included in the present study for
comparison purposes, were prepared by reacting 4 (R1 = H,
R2 = R3 =Me) with acetic anhydride (5 mol equiv), HOBt,
and DIC inN,N-dimethylformamide (DMF) and in refluxing
neat acetic anhydride (20 mol equiv), respectively.29
Biology. Antiplasmodial Activity and Cytotoxicity. All
compounds 5 were evaluated for in vitro antiplasmodial
activity against the chloroquine-resistant P. falciparum
strain W2 (Table 1). Compound toxicity was evaluated by
assessing effects on the viability of A549 human adenocarci-
noma epithelial lung cells. Inspection of the data in Table 1
allows the following observations:
i The in vitro antiplasmodial activity of compounds 5 is
not significantly affected by the nature of the amino acid
Scheme 2. Synthetic Route to Imidazoquines 5 and Their Acetyl Analogues 6 and 7a
aReagents and conditions: (i) 1 equiv BocAAOH, 1.1 equiv DIC, 1.1 equiv HOBt, 1 equiv triethylamine (TEA), dichloromethane (DCM), 0 Cf rt;
(ii) TFA, rt, 30% aq Na2CO3, extraction with CHCl3; (iii) excess propanone, 1 equiv TEA, molecular sieves, refluxingMeOH; (iv) 5 equiv BocAAOH,
5 equiv DIC/HOBt, 3 equiv TEA, DMF, -10 C f rt, inert atmosphere; (v) TFA/DCM 30%, rt, followed by Na2CO3 aq 30% and extraction with
DCM; (vi) 5 equiv Ac2O, 5 equiv DIC/HOBt, 3 equiv TEA, DMF, -10 Cf rt, inert atmosphere; (vii) refluxing neat Ac2O (20 equiv).
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residue at the imidazolidin-4-one’s N-1 atom. For ex-
ample, the glycine derivative 5a (R2 = H) is equipotent
to its leucine counterpart, 5d (R2 = i-Bu) and only ∼2
times more active than its methionine counterpart, 5f
(R2 = CH2CH2SMe).
ii The activity of compounds 5 is also not significantly
affected by the nature of the R1 substituent at the C-5
position of the imidazolidin-4-one moiety, as indicated
by the similar IC50 values for compounds 5a and 5h.
This result contrasts sharply with that of precursors 4,
in which the incorporation of a methyl group at C-5
leads to complete loss of activity (4a vs 4b).28
iii Acetylation of the imidazolidin-4-one’s N-1 atom leads
to complete loss of activity (e.g., 6 vs 5a), suggesting
that the presence of a basic amino group is a major
requirement for antiplasmodial activity. This result is
in line with previous reports on the importance of such
group for the antimalarial activity of 8-aminoquino-
lines.18,31,32
iv In general, compounds 5 displayed greater cytoxicity
than PQ against A549 cells, with the exception of 5a
and 5h (i.e., the third most active and the most active
compounds in the series, respectively), which showed
no toxicity in this assay. Compound 5d also presented a
favorable cytotoxicity/antiplasmodial ratio of 3.5.
Overall, these results suggest that the antiplasmodial
activity of compounds 5 benefits from the N1-acylation of
the imidazolidin-4-one ring with an amino acid. This fact
may be partly due to the presence of the primary amino
group brought by the inserted amino acid residue. This
hypothesis is strengthened by the fact that N-acetylated
derivatives 6 and 7 were found to be devoid of blood-
schizontocidal activity.
Anti-Plasmodium Liver Stage Activity. Given the tissue-
schizontocidal activity of PQ and the fact that compounds 4
and 5 presented biological properties similar to those of the
parent drug, it was predicted that the two sets of PQ imida-
zolidin-4-ones would be similarly active against liver forms of
Plasmodia. To assess the ability of compounds 5 to inhibit the
development ofP. berghei schizonts in humanhepatoma cells,
we employed a recently described fluorescence activated cell
sorting (FACS)-basedmethod.33 This method is based on the
measurement of the fluorescence of Huh-7 cells, a human
hepatoma cell line, following infection with GFP-expressing
P. berghei sporozoites. At a given time after infection, the
percentage of parasitized cells is given by the percentage of
GFP-positive events (Figure 1A). Because GFP expression is
under the control of the house-keeping EF1R promoter, the
extent of intracellular development is proportional to the
number of GFP copies in the cell, measured as the intensity
of fluorescence (Figure 1A). The hepatic anti-plasmodial
activity of compounds 5 was monitored by measuring infec-
tion of Huh-7 cells incubated with various concentrations of
each, 48 h after sporozoite addition. The presence of these
compounds decreased the number of GFP positive Huh-7
cells to different extents when compared with control values,
albeit less so than the parent PQ (Figure S1 in Supporting
Information).Most importantly, all compounds 5 displayed a
marked, dose-dependent effect on parasite development
(Figure 1B; Table 1). The IC50 values of all the compounds
in terms of their ability to impair the development of
P. berghei liver schizonts were determined following the
process depicted in Figure 1C. Although IC50 values for
compounds 5were higher than that of PQ, several compounds
displayed marked antiplasmodial activity, with their ranking
following the order 5b≈ 5e< 5c< 5a≈ 5g≈ 5h< 5d< 5f.
Table 1. Cytotoxicity, Anti-Pneumocystis Activity, and Antiplasmodial Activity of Compounds 1, 4a,b, 5a-h, 6, and 7 against Blood-Stage P.
falciparumW2 and Liver-Stage P. berghei
anti-P. carinii activity
IC50 in μM (μg/mL)
a
compd R1 R2
activity against
blood stage forms
IC50 (μM)
activity against
liver stage forms
IC50 (μM) 24 h 48 h 72 h
cytotoxicity (A549 cells)b
IC50 at 72 h in μM (μg/mL)
1 3.3 2 18.1 (4.7) 8.5 (2.2) 3.5 (0.9) >100
4a H 9.1c 23 (8.3)c
4b Me >50c 226 (83.7)c
5a H H 6.7 22 43.8 (18.1) 37.5 (15.5) 28.1 (11.6) >100
5b H CH3 8.0 10 39.6 (16.9) 18.7 (8.0) 8.4 (3.6) 7.8
5c H CHMe2 7.9 17 54.3 (24.7) 20.2 (9.2) 13.6 (6.2) 5.5
5d H CH2CHMe2 6.3 24 31.1 (14.6) 17.9 (8.4) 10.9 (5.1) 21.2
5e H CH(Me)Et 8.7 13 27.5 (12.9) 16.0 (7.5) 9.8 (4.6) 14.9
5f H (CH2)2SMe 12.5 31 23.8 (11.6) 13.1 (6.4) 7.0 (3.4) 7.9
5g H CH2Ph 9.9 21 24.0 (12.1) 18.5 (9.3) 10.1 (5.1) 9.1
5h Me H 5.5 21 inactive 75.4 (32.2) 52.2 (22.3) >100
6 H >10.0 ND inactive 101.7 (40.5) 36.7 (14.6) >100
7 H >10.0 ND inactive inactive inactive >100
aDrug activity scale: highly active, <0.01 μg/mL; very marked, <0.1 μg/mL; marked, 0.1-0.99 μg/mL; moderate, 1.0-9.9 μg/mL; slight, 10.0-
49.9 μg/mL; inactive g 50.0 μg/mL.40 bHuman epithelial lung adenocarcinoma cell line. cTaken from reference 28.
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Anti-PneumocystisActivity.The antifolate combination of
trimethoprim and sulfamethoxazole (TMP-SMX) has been
used for both prophylaxis and treatment of pneumocys-
tosis,34,35 but development of microbial resistance and aller-
gic reactions against the sulfa component often require the
use of alternative therapies,32-34 among which is PQ, used in
combination with clindamycin.35 Previous work suggests
that there is a synchrony between the structure-activity
relationships (SARs) presented by PQ-related drugs for
malaria and pneumocystosis.34,36-39 Therefore, imidazoli-
din-4-ones 5 were evaluated against P. carinii in an
ATP detection assay based on the release of biolumine-
scence driven by ATP in a luciferin-luciferase mediated
reaction.40,41 All compounds, as well as PQ, reduced the
ATP pools in P. carinii in a dose- and time-dependent
manner. The maximal effect for compounds 5 was seen at
72 h with IC50 values ranging from 7 to 52 μM, i.e., from
moderate to slight activity in the usual scoring scale42 while
PQ presented an IC50 of 3.5 μM at 72 h (Table 2). Activity
Figure 1. Flow cytometry-based Plasmodium liver stage infection assays. (A) Representative dot plots (left) and histograms (right) of a
control sample of Huh7 cells infected with GFP-expressing P. berghei parasites, analyzed 48 h after sporozoite addition; the GFP-positive
cells, in a total of 50000 acquired events, corresponds to fraction of infected cells (left), while the geometric mean of the distribution of
fluorescence intensities in the GFP-positive population corresponds to the intracellular development of the parasites (right). (B) Dose-
dependencies of parasite development in cells infected in the presence of increasing concentrations of the various compounds tested,
relative to that of solvent-treated samples in the same experiment. (C) Example of the calculation of the IC50 for inhibition of parasite
development; (left) representative histograms of the distribution of fluorescence intensities in the GFP-positive population of cells infected
in the presence of different concentrations of compound and of the corresponding solvent control; (center) geometric means of
fluorescence intensities relative to that of the solvent-treated control; (right) sigmoidal curve of fluorescence intensities as a function of
the logarithm of compound concentration; the example pertains the parent compound primaquine (green), with the solvent-treated control
shown in red and the value of the IC50 shown as an orange sphere; only 4 out of 6 data points are shown to facilitate viewing of the histogram
lines.
Table 2. Effect of Compounds 1 and 5a,b,e-h on the Sporogonic
Development of Plasmodium berghei ANKA in Anopheles stephensi
compd dose/μmol 3 kg
-1
mean no. of oocysts
per mosquito ( SEMa
% of infected
mosquitoes
1 10 3.5( 1.2 40.0
50 0.2( 0.2 2.9
5a 10 1.1( 0.2 42.5
50 0.8( 0.3 40.5
5b 10 9.7( 2.5 67.9
50 1.3( 0.3 40.1
5e 10 4.9 ( 0.6 83.3
50 1.5( 0.5 62.2
5f 10 1.2( 0.4 47.1
50 3.8( 1.4 26.4
5g 10 3.7( 1.2 43.8
50 2.2 ( 0.8 40.0
5h 10 3.3( 1.1 62.0
50 1.8( 0.5 37.5
control 0 8.2( 1.2 72.1
a Standard error of the mean.
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was not significantly affected by the nature of the side chain
at the terminal amino acid residue, i.e., R2. For example,
compounds 5b (R2 =Me), 5d (R2 = iso-Bu), 5e (R2 = sec-
Bu), 5f (R2=CH2CH2SMe) had less than 3-fold variation in
IC50 values from compounds 5a-5g. The N1-acetyl deriva-
tive 6, which is a desamino analogue of imidazoquines 5,
although clearly much less active than the latter, did display
some activity after 72 h. This result indicates that IC50 values
decrease over time and that all compounds assayed inhibit
P. carinii development after 72 h, with the exception of theN,
N0-diacetyl derivative 7. These results suggest that PQ’s
secondary amino group attached to the quinoline’s C-8 has
a role in antipneumocystis activity. Remarkably, the N1-
acyl-imidazolidin-4-ones 5 showed activity as soon as 48 h
after initiation of incubation, which represents an improve-
ment over most of their imidazolidin-4-one precursors 4 that
were only visibly active after 72 h. Moreover, at 72 h, most
compounds 5 were slightly more effective than their precur-
sors 4, as illustrated by comparison of compound 4.2 (R1 =
R2=R4=CH3; IC50 at 72 h=226 μM)
28 with itsN1-glycyl
derivative 5h (IC50 at 72 h= 52 μM).
The relative positions of the two amino acid building
blocks (i.e., switching between R1 and R2) also seems im-
portant, as shown by comparison of compound 5h with its
isomer 5b (IC50 at 72 h= 8.4 μM).
Overall, these data show a certain degree of parallelism
between the antiplasmodial and antipneumocystis activities
of 8-aminoquinolinic compounds, as N1-acylation of imida-
zolidin-4-ones 4 (to yield 5) seems to be beneficial both for
the blood-schizontocidal and for the antipneumocystis ac-
tivity of these compounds. However, the most efficient
compounds againstP. falciparumwere not those that ranked
the best against P. carinii.
In Vivo Transmission-Blocking Activity. The potential of
compounds 5 to inhibit the sporogonic cycle of Plasmodia
within themosquito gutwas studied using amodel consisting
of Balb/C mice infected with P. berghei and Anopheles
stephensi mosquitoes and compared to that of PQ.26 The
activity was measured by the percentage of mosquitoes with
oocysts and the mean number of oocysts per infected mos-
quito (Table 2). Although this model cannot specifically
attribute the drug effect to either gametocytocidal or spor-
ontocidal activity, it can clearly show if a compound is
effective at interrupting the transmission of the infection to
mosquitoes by interference with the cycle in these insects.26
Compounds were tested at 10 and 50 μmol 3 kg
-1 and,
although none of them was particularly good at decreasing
the percentage of infectedmosquitoes, all of themwere active
at effectively reducing the mean number of oocysts formed
per infected mosquito. Moreover, while none of them was
superior to PQ at the highest dose, at the lowest dose two of
them (5g,h) were comparable to and two others (5a,f) were
better than the parent drug. Compound 5a significantly
reduced (P < 0.05) the sporogonic development of the
parasite at both doses tested, while compound 5b was
inactive at 10 μmol/kg. Interestingly, 5e was clearly active
but did not rank the best of the set, in contrast to its relative
activity against liver-stage P. berghei. Results also show that
there is no correlation between transmission-blocking and
anti-P. carinii activities, as previously noticed for imidazoli-
din-4-one precursors 4.28
Physicochemical Properties and Plasma Stability. Several
parameters were calculated for imidazolidin-4-ones 5 in
order to gain some insight to their drug-likeness: molecular
weight, HBD, HBA, logP, logS, and Drug Score (see Table
S1 in Supporting Information).43,44 All imidazoquines 5
have molecular weights below 500 Da (except for 5g that
weighs 503 g/mol), less than five hydrogen bond donors
(all compounds 5 have three HBD), less than 10 hydrogen
bond acceptors (all compounds 5 have five HBA) and
estimated45,46 octan-1-ol/water partition coefficients (logP)
below 5 (Table S1, Supporting Information). While imida-
zolidin-4-one precursors 4a,b have slightly increased lipo-
philicities with respect to PQ, but at the expense of
significantly decreased water-solubility, imidazoquines de-
rived fromAla (5b,h) have only slightly reduced lipophilicity
(logP respectively of 2.49 and 2.57, as compared to 2.76 for
PQ) accompanied by a remarkable increment on their water-
solubility (0.12 g/L as compared to 56.4 mg/L for PQ).
Finally, drug scores were consistently higher for compounds
5 and 4a,b than that for the parent compound. We also
determined the stability of compounds 5 in 80% human
plasma,26,27 which was found to be remarkably high, with no
degradation detected after three days of incubation. Impor-
tantly, stability was not affected by the substitution pattern
at the terminal amino acid or the imidazolidin-4-one moiety.
Such stability had already been reported on previous studies
involving some of these imidazoquines and their precursors
4.25-27,47,48 Overall, these results suggest that the oral avail-
ability of compounds 5 is unlikely to be limited by compound
stability.
Conclusions
Imidazoquines, i.e., peptidomimetic derivatives of PQ with
general structure 5, are stable compounds that preserve the
overall bioactivity pattern of the parent drug. Because of
blockage of the aliphatic amine of PQ by insertion of the
peptidomimetic carrier, structures 5 are not vulnerable to
oxidative deamination, which is the main metabolic process
behind the low oral bioavailability of PQ. On the other hand,
the use of a peptidomimetic instead of a dipeptide carrier
makes compounds 5 stable to proteolytic degradation by
action of amino- or endopeptidases.
It is well established that the main problem of PQ, which is
still the only drug in clinical use to treat hypnozoites of vivax
and ovale malaria, is of metabolic nature, as metabolic
transformations are behind both PQ’s low bioavailability
and serious hematotoxicity, especially for people deficient in
6GPD. Consequently, even though most imidazoquines 5
were generally not as active as the parent PQ, their remarkable
chemical and enzymatic stability, as well as preliminary data
on their ADME properties, suggest that they are promising
leads toward novel hydrolytically- and enzimatically stable
drugs with therapeutic indices superior to that of primaquine,
useful against malaria and pneumocystosis.
Experimental Section
Chemistry. For compound synthesis, NR-protected amino
acids and NR-protected dipeptides from Bachem (Switzerland)
were used. Solvents were of p.a. quality, from Merck (VWR
International, Portugal). When required, solvents were pre-
viously dried with preactivated molecular sieves (4 A˚)
(Merck). Both thin layer chromatography (TLC) aluminum foil
plates covered with silica 60 F254 (0.25 mm) and silica-gel 60
(70-230 mesh ASTM) for preparative columm chromatogra-
phy were also fromMerck. Other chemicals (DIC, HOBt, TEA,
TFA) were from Sigma-Aldrich.
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The purity degrees of all compounds were checked to be
higher than 95%, as determined by HPLC using a Merck
Hitachi ELITE LaChrom equipped with an L-2130 pump, an
L-2200 autosampler, and an L-2455 diode-array detector.
Samples were injected on a Merck Purospher STAR RP-18e
125 cm  4.6 mm (5 μm) column equipped with a Merck
Lichrocart precolumn (Merck, Germany). Analyses were run
by either isocratic or gradient methods (see Supporting Infor-
mation for details) at a 1 mL/min flow rate. Chromatograms
recorded at 265 nm are given in the Supporting Information.
NMR spectra of compounds dissolved in deuterated chloro-
form (CDCl3), containing tetramethysilane (TMS) as internal
reference, were acquired on a Bruker AMX-300 spectrometer.
Mass spectrometry (MS) was performed either by the matrix-
assisted laser desorption ionization-time-of-flight (MALDI-
TOF) technique, on an Applied Biosystems Voyager STR-DE
spectrometer using either anthracene or 2,5-dihydroxibenzoic
acid (DHB) as adjuvant matrices, or by the electrospray ioni-
zation-ion trap (ESI-IT) technique on a Finnigan Surveyor
LCQ DECA XP MAX quadrupole mass spectrometer.
General Procedure for the Synthesis of Imidazoquines 5a-h.
The synthetic route followed is depicted in Scheme 2. Synthesis
detailed procedures, percentage yields, and analytical/spectro-
scopic data for all test compounds, with the exception of 5e and
its Boc-protected precursor Boc-5e, have been described else-
where.25,26,29
Briefly, PQ (1) was coupled to the relevant Boc-protected
amino acid to produce Boc-3, which was then deprotected by
acidolysis to give the trifluoroacetic acid salt of 3 that was
converted to the free base (3) by addition of 30% aq Na2CO3
until pH 10 was reached, followed by extraction with chloro-
form (Scheme 2 and respective legend).25,26 Each compound 3
(2 equiv) was then mixed with an excess (4 equiv) of propanone
in dry methanol (10 mL) containing triethylamine (TEA,
2 equiv), and the mixture was refluxed for 3 days in the presence
of 4 A˚molecular sieves (1 g).25,26 The reaction wasmonitored by
TLC and propanone was readded (2 equiv) once per day. The
molecular sieves were removed by decantation and the solution
was evaporated to dryness, producing an oily residue that was
submitted to column chromatography on silica gel. The product
was isolated as yellow-orange oil and correctly identified as the
target imidazolidin-4-one 4 (Scheme 2).25,26
Compounds 4 (1 equiv) were dissolved in DMF (20 mL)
containing TEA (3 equiv), and themixture was stirred at-10 C
for 20 min under inert atmosphere. The appropriate Boc-
protected amino acid (5 equiv) was added together with DIC
(5 equiv) and HOBt (5 equiv), and the suspension was kept at
-10 C for further 4 h, under stirring. The temperature was then
increased to 10 C and thus maintained until the end of reaction
(24 h by TLC). The solid was removed by vacuum filtration, and
the filtrate was evaporated to dryness in vacuum at 90 C,
yielding a residue that was dissolved in 40 mL of DCM. This
solution was washed three times with 15mL portions of 10% aq
NaHCO3 and the organic layer dried over anhydrous MgSO4
and evaporated to dryness. The residue was submitted to
column chromatography on silica using DCM/acetone, to give
the Boc-protected imidazoquines, Boc-5, as yellow-orange oils
presenting correct spectral data.26,29 Each compoundBoc-5was
then dissolved in TFA at 30% in DCM, and the reaction was
allowed to proceed for 2 h at room temperature. Then 30% aq
Na2CO3 was added to the resulting trifluoroacetic acid salt of 5
until pH 10, and the supernatant oily layer formedwas extracted
six times with 10 mL portions of chloroform. The organic layers
were pooled, dried over anhydrous MgSO4, and evaporated to
dryness, yielding a chromatographically homogeneous yellow-
orange oils that were identified as the target structures 5.26,29
1-(N-tert-Butoxycarbonyl)isoleucyl-3-(4-(6-methoxyquinolin-
8-ylamino)pen-tyl)-2,2-dimethylimidazolidin-4-one (Boc-5e). 1H
NMR (400MHz, CDCl3) δ 0.86-0.83 (m, 6H), 1.24 (d, 3H, J=
6.4 Hz), 1.37 (s, 9H), 1.54-1.53 (sþs, 6H), 1.82-1.58 (m, 7H),
3.27-3.10 (m, 2H), 3.61-3.55 (m, 1H), 3.82 (s, 2H), 3.97-3.91
(m, 1H), 4.01 (d, 1H, J= 15.0 Hz), 4.36 (d, 1H, J= 14.9 Hz),
4.97 (d, 1H, J= 9.0 Hz), 6.22 (d, 1H, J= 2.5 Hz), 6.26 (d, 1H,
J= 2.5 Hz), 7.23 (dd, 1H, J= 4.2, 8.3 Hz), 7.85 (dd, 1H, J=
1.6, 8.3Hz), 8.45 (dd, 1H, J=1.6, 4.1Hz). 13CNMR(100MHz,
CDCl3) δ 9.58, 13.93, 19.22, 22.91, 23.57, 24.31 þ 24.36, 26.00,
26.82, 32.62 þ 32.65, 35.94, 36.61, 38.39, 46.39, 47.14, 50.50,
53.76, 55.52, 78.36, 79.34, 90.32, 95.35, 120.41, 128.45, 133.35,
133.85, 142.86, 143.47, 154.42, 157.95, 164.35, 169.08.m/z [Mþ
Hþ]= 570.8003 (calcd 570.3655); [MþNaþ]= 592.7314 (calcd
592.3475).
1-Isoleucyl-3-(4-(6-methoxyquinolin-8-ylamino)pentyl)-2,2-
dimethylimida-zolidin-4-one (5e). 1HNMR (400MHz, CDCl3) δ
0.87-0.74 (m, 3H), 1.12-0.96 (m, 3H), 1.25 (d, 3H, J=6.4Hz),
1.57-1.54 (m, 2H), 1.55-1.54 (sþs, 3H), 1.57-1.56 (sþs, 3H),
1.82-1.60 (m, 7H), 3.06 (d, 1H, J=6.2Hz), 3.23-3.12 (m, 2H),
3.62-3.54 (m, 1H), 3.82 (s, 3H), 4.03-4.01 (sþs, 2H), 5.94
(d, 1H, J= 8.4 Hz), 6.22 (d, 1H, J= 2.5 Hz), 6.27 (d, 1H, J=
2.5 Hz), 7.24 (dd, 1H, J = 4.2, 8.2 Hz), 7.85 (dd, 1H, J = 1.6,
8.3 Hz), 8.45 (dd, 1H, J = 1.6, 4.2 Hz). 13C NMR (100 MHz,
CDCl3) δ 10.31, 15.09, 19.69, 22.60, 23.37, 24.78, 28.68, 33.09,
37.94, 38.84, 47.36, 54.21, 57.38, 79.80, 90.74, 92.63, 95.76,
120.86, 128.88, 133.77, 134.32, 143.32, 143.92, 158.38, 164.75,
171.91. m/z [M þ Hþ] = 470.0712 (calcd 470.3131).
Biology. In Vivo Transmission-Blocking Activity Assays.
Balb/C mice were infected by intraperitoneal inoculations of
107 erythrocytes parasitized with P. berghei ANKA. After
4 days, when the presence of gametocytes was observed by
microscopic observation of Giemsa stained blood films, mice
were randomly separated into eight different groups of six
animals. Each group was treated by intraperitoneal administra-
tion with one single dose of each compound 5 and PQ (10 and
50 μmol/kg in inoculation volumes of 0.1-0.2 mL; controls
consisted of mice given a PBS solution). Two hours after
administration, mice were anesthetized and placed on top of
individual cages containing ca. 50 glucose-starved Anopheles
stephensi female mosquitoes, which were allowed to feed for 2 h.
After the blood meal, unfed female mosquitoes were removed
from each cage. Ten days after the bloodmeal, 10mosquitoes of
each cage were randomly collected and dissected for micro-
scopic detection of oocysts in midguts.
In Vitro Blood-Schizontocidal Activity Assays. These assays
have been conducted as reported elsewhere.28,32,49-52 Briefly,
synchronized ring-stage W2 strain P. falciparum parasites were
culturedwithmultiple concentrations of test compounds (added
from 1000 stocks in DMSO) in RPMI 1640mediumwith 10%
human serum. After a 48 h incubation, when control cultures
contained new rings, parasites were fixedwith 1% formaldehyde
in PBS, pH 7.4, for 48 h at room temperature and then labeled
with YOYO-1 (1 nM; Molecular Probes) in 0.1% Triton X-100
in PBS. Parasitemias were determined from dot plots (forward
scatter vs fluorescence) acquired on a FACSort flow cytometer
using CELLQUEST software (Becton Dickinson). IC50s for
growth inhibition were determined with GraphPad Prism soft-
ware from plots of percentages of the level of parasitemia of the
control relative to inhibitor concentration. In each case, good-
ness of curve fit was documented by R2 values of >0.95.
In Vitro Plasmodium Liver Stage Infection Assays. Cells and
Parasites. Huh-7 cells, a human hepatoma cell line, were cul-
tured in 1640 RPMI medium supplemented with 10% v/v fetal
calf serum (FCS), 1% v/v nonessential amino acids, 1% v/v
penicillin/streptomycin, 1% v/v glutamine, and 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES), pH
7, and maintained at 37 C with 5% CO2. For infection assays,
Huh-7 cells (7  104 per well) were seeded in 24-well plates the
day before drug treatment and infection. Medium in the
cells was replaced by medium containing the appropriate con-
centration of each compound immediately prior to infection
by addition of 30000 sporozoites, followed by centrifuga-
tion at 1700g for 5 min at 37 C. GFP-expressing P. berghei
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(parasite line 259 cL2) sporozoites were obtained by disruption
of the salivary glands of freshly dissected infected female
Anopheles stephensi mosquitoes.
Parasite Development Assays. Intracellular parasite develop-
ment was determined by measuring GFP intensity in cells
infected with GFP-expressing P. berghei parasites by fluores-
cence-activated cell sorting (FACS), as previously described.33
Briefly, cell samples for FACS analysis were washed with 1 mL
of phosphate buffered saline (PBS), incubated with 100 μL of
trypsin for 5 min at 37 C, and collected in 400 μL of 10% v/v
FCS in PBS at the selected time points post sporozoite addition.
Cells were then centrifuged at 0.1g for 5 min at 4 C and
resuspended in 150 μL of 2% v/v FCS in PBS. Cells were
analyzed on a Becton Dickinson FACScalibur with the appro-
priate settings for the fluorophore used. Data acquisition and
analysis were carried out using theCELLQuest (version 3.2.1fl1,
BectonDickinson) andFlowJo (version 6.3.4, FlowJo) software
packages, respectively.
In Vitro Anti-P. cariniiActivity Assays. P. cariniiOrganisms.
Organisms for the ATP assays were obtained from chronically
immunosuppressed Long Evans and Brown Norway rats
housed under barrier conditions at the Cincinnati VA Medical
Center (VAMC) and inoculated intratracheally with P. carinii.
These were extracted and purified from the lungs of rats after
8-12 weeks of immunosuppression, enumerated, cryopre-
served, and stored in liquid nitrogen. Typically, infected rat
lungs yield up to 2 1010 organism nuclei with the vast majority
(about 95%) of the life cycle forms present as trophic forms with
the remainder (about 5%) being composed of cysts. P. carinii
preparations were evaluated for microbial contamination, ATP
content, karyotype, and host cell content prior to use in theATP
assay.
ATP Assay. Isolated organisms used for ATP analyses were
suspended in a supplemented RPMI 1640 medium containing
20% calf serum and other additives, pH 7.5-8.0, 380 mOsm, as
previously described.40Drugs were added to the culturemedium
in DMSO (the final concentration of DMSO was <0.2%, vol/
vol), and 108 organisms (as total nuclei) per mL were added to
1-2 mL of the culture medium in multiwell plates. For every
assay, each drug concentration was assayed in triplicate using
different organism isolation batches. The final ATP content was
expressed as the average relative light units of nine values (three
readings per well). To assess the effects of extended exposure to
PQ and imidazoquines, the ATP contents of cultures sampled
after 24, 48, and 72 h of incubation at 35 C in a 10% CO2
humidified atmosphere were measured. The media of all wells
were changed on a daily basis after centrifugation of the multi-
well plates at 2400g and removal of the previous medium. The
ATP content was determined by the luciferin-luciferase assay as
described previously and was expressed as relative light units.40
The effects of the compounds on theP. cariniiATP content were
compared with the ATP contents of P. carinii populations that
did not receive experimental compounds and expressed as
percentages of these control values. In addition, other controls
for each assay included quench controls to evaluate the effects of
the highest drug concentrations used on the luciferase-luciferin
reaction; vehicle controls to evaluate the effects of any solvent
on the same reaction and on the organism ATP content.
Cytotoxicity Assays. Preparations with less than 85% viabi-
lity were not used in the cytoxicity assay. After enumeration,
organisms were added to 24-well plates containing 1 to 2 mL of
RPMI supplemented with 20% FBS, vitamins, minerals, and
other additives at a standard density of 108/mLwith orwithout a
test compound. At least three concentrations of each compound
were evaluated (10, 1.0, and 0.1 μg/mL) by incorporation into
themedium. Triplicate wells were used for each concentration of
test compound evaluated and for control groups.40
Compound Stability in Human Plasma. HPLC Analysis.
HPLCmeasurements were carried out using aWaters assembly
equipped with a model 600 controlled pump and a model 991
photodiode-array detector. A Rheodyne 7725 injection valve
equipped with 20 μL sample loop was used. Acquisition and
treatment of data were made by means of NEC for MS-DOS,
version 3.30 software. The separation was performed on a
Purospher, 250 mm  4.0 mm i.d. 5 μm (Merck, Germany)
analytical column. A LiChrospher 100 RP-8 5 μm (Merck,
Germany) was employed as precolumn. The solvent system
used was a gradient of sodium acetate buffer (pH 4.75;
0.05 M) (A) and acetonitrile (B); 10-3 M triethylamine was
added to the aqueous mobile phase in order to improve peak
shape. The gradient was as follows: 0 min, 50%B; 4.5 min, 50%
B; 5.0 min, 10% B; 20 min, 10% B. Elution was performed at a
solvent flow-rate of 1 mL/min and a 15 mL/min nitrogen
sparging was applied to remove dissolved gases. Chromato-
graphic separation was monitored by UV detection at 265 nm.
All analyses were performed at room temperature.
Hydrolysis in Human Plasma. Compounds 5 were incubated
at 37 C in human plasma (from heparinized blood of healthy
donors) diluted to 80% (v/v) with pH 7.4 isotonic phosphate
buffer. At appropriate intervals, aliquots were added to acet-
onitrile to quench the reaction and precipitate plasma proteins.
These samples were centrifuged and the supernatant analyzed
by the HPLC method described above for the presence of
substrate and products.
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